| Topic | |
| Introduction to DMARDs– a concept to current understanding | |
| Pre-evaluation for use of DMARDs | |
| Methotrexate | |
| Pharmacology, pharmacodynamics and mechanism | |
| Clinical use of methotrexate in rheumatology- | |
| Safety concern, precautions and management of adverse events | |
| Hydroxychloroquine | |
| Pharmacology, pharmacodynamics and mechanism | |
| Clinical use in rheumatology- Safety concern, precautions and management of adverse events | |
| Leflunomide | |
| Pharmacology, pharmacodynamics and mechanism | |
| Clinical use in rheumatology- Safety concern, precautions and management of adverse events |
|
| Sulfasalazine | |
| Pharmacology, pharmacodynamics and mechanism | |
| Clinical use in rheumatology- Safety concern, precautions and management of adverse events | |
| Iguratimod | |
| Pharmacology, pharmacodynamics and mechanism | |
| Clinical use in rheumatology- Safety concern, precautions and management of adverse events | |
| Other DMARD | |
| Azathioprine, Cyclosporine, D-penicillamine and Gold | |
| DMARD in special situation Part I | |
| DMARD in special situation Part II | |